No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.
www.chemiphar.co.jpNo one on the platform currently holds 4539.T.
No tracked institution reports a position in 4539.T as of their last filing.
No one on the platform has traded 4539.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4539.TNippon Chemiphar Co., Ltd. | $1550.00 | +0.00% | $5.6B | — |
| 2796.TPharmarise Holdings Corporation | $505.00 | -0.39% | $5.8B | — |
| 3386.TCosmo Bio Company,Limited | $1240.00 | -0.24% | $7.0B | — |
| 4582.TSymBio Pharmaceuticals Limited | $56.00 | +0.00% | $3.1B | — |
| 4586.TMedRx Co., Ltd | $61.00 | +1.67% | $3.6B | — |
| 4883.TModalis Therapeutics Corporation | $32.00 | -3.03% | $3.1B | — |
| 4892.TCyfuse Biomedical K.K. | $670.00 | +0.45% | $6.8B | — |
Source: Financial Modeling Prep · peers by sector/industry